Compare Jabil Inc (JBL) vs TG Therapeutics Inc (TGTX) Price & Performance

JBL stock trades at $366.16, up 8.77% in the last session, reflecting strong momentum driven by AI infrastructure demand. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.16 exceeding the $3.10 forecast. Technical indicators show a bullish trend with the stock approaching resistance near $371, while fundamentals reveal solid revenue growth projections from $29.8B in 2025 to $33.6B in 2026.

JBL presents compelling growth potential as an AI infrastructure play with projected revenue exceeding $20B by 2027, though elevated P/E of 44.63 and thin net margins of 2.57% warrant caution. Analyst consensus targets $448.29 (22% upside) with balanced buy/hold ratings. Key risks include execution challenges in scaling AI operations and competitive pressures in electronics manufacturing services.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.